CASP4 and colonic neoplasm: It is interesting to note that among the top ~50% of SDC1 and among which the top 20% CASP4 high-expressing lung adenocarcinoma and colon cancer patients (out of 503 for lung and 524 for colon, respectively), approximately 20 (lung) and 50 (colon)% of them possess KRAS mutations (Supplementary Tables S2 and S3).